European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation. pandemic influenza vaccine should be used in accordance with official guidance.

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238; a/darwin/9/2021 (h3n2) - like strain (a/darwin/9/2021, ivr-228); b/austria/1359417/2021 - like strain (b/michigan/01/2021, wild type); b/phuket/3073/2013 -like strain (b/phuket/3073/2013, wild type) - suspension for injection in pre-filled syringe - 15 microgram(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen

European Union - English - EMA (European Medicines Agency)

sanofi pasteur s.a. - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of idflu should be based on official recommendations.

European Union - English - EMA (European Medicines Agency)

sanofi pasteur europe - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of intanza should be based on official recommendations.

Ireland - English - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - a/victoria/4897/2022 (h1n1)pdm09-like strain (a/victoria/4897/2022, ivr-238; a/darwin/9/2021 (h3n2)-like strain (a/darwin/6/2021, ivr-227); b/austria/1359417/2021 - like strain (b/austria/1359417/2021, bvr-26) [victoria lineage]; b/phuket/3073/2013 -like strain (b/phuket/3073/2013, wild type) - suspension for injection in pre-filled syringe - 15 international unit(s) - influenza vaccines; influenza, inactivated, split virus or surface antigen

Malta - English - Medicines Authority

mylan products limited - influenza vaccine (split virion, inactivated) - suspension for injection in pre-filled syringe - influenza vaccine (split virion, inactivated) 15 µg - vaccines

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

split virion, inactivated) high dose suspension for injection 0.5ml pre-filled syringes (sanofi pasteur - influenza virus inactivated split (h1n1, h3n2-like, b/brisbane/60/2008-like, strains) - suspension for injection

Malta - English - Medicines Authority

mylan ire healthcare limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - influenza vaccine, split virion, inactivated - suspension for injection in pre-filled syringe - influenza vaccine (split virion, inactivated) 15 µg - vaccines

European Union - English - EMA (European Medicines Agency)

sanofi pasteur s.a. - split influenza virus, inactivated, containing antigen*: a/california/7/2009 (h1n1)v like strain (x-179a)*propagated in eggs. - influenza, human; immunization; disease outbreaks - vaccines - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.

United States - English - NLM (National Library of Medicine)

novartis vaccines and diagnostics ltd - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) (unii: k9p8pva2ug) (influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) - unii:k9p8pva2ug) - influenza a virus a/california/7/2009(h1n1)-like hemagglutinin antigen (propiolactone inactivated) 15 ug in 0.5 ml - influenza a (h1n1) 2009 monovalent vaccine is an inactivated influenza virus vaccine indicated for immunization of persons 4 years of age and older against influenza disease caused by pandemic (h1n1) 2009 virus. influenza a (h1n1) 2009 monovalent vaccine should not be administered to anyone with known systemic hypersensitivity reactions to egg proteins (eggs or egg products), or to any component of influenza a (h1n1) 2009 monovalent vaccine, or who has had a life-threatening reaction to previous influenza vaccinations [see description (11)]. novartis’ influenza a (h1n1) 2009 monovalent vaccine and seasonal trivalent influenza virus vaccine (fluvirin) are manufactured by the same process. available information for fluvirin is provided in this section. pregnancy category c: animal reproduction studies have not been conducted with influenza a (h1n1) 2009 monovalent vaccine or fluvirin. it is also not known whether influenza a (h1n1) 2009 monovalent vaccine or fluvirin can cause fetal harm when administered to